Wesfarmers 1st Half Profit Rises 3%, Boosted by Retail
By Mike Cherney
SYDNEY--Australian industrial-retail conglomerate Wesfarmers said its half-year profit rose 3%, reflecting strong performance in retail but a drag from lower commodity prices.
The company, which runs retail chains like hardware store Bunnings and discount chain Kmart and has fertilizer, lithium and healthcare businesses, said its net profit for the six months through December was 1.425 billion Australian dollars (US$930 million). That's slightly ahead of market expectations for A$1.398 billion, as assessed by FactSet.
Revenue rose 0.5% to A$22.67 billion. That compares to market expectations for A$22.79 billion, according to FactSet. The rise was driven by Kmart, where revenue rose 4.8%, and Bunnings, where revenue grew 1.7%, and offset by the chemicals, energy and fertilizer unit, where revenue fell 21%.
Wesfarmers said it would pay an interim dividend of 91 cents, versus 88 cents a year ago.
Write to Mike Cherney at mike.cherney@wsj.com
(END) Dow Jones Newswires
February 14, 2024 16:52 ET (21:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track